JavaScript is unavailable or disabled; so you are probably going to miss out on a few things. Everything should still work, but with a little less pzazz! Skip to main content
The William Harvey Research Institute - Barts and The London

Professor Sir Mark Caulfield


Professor of Clinical Pharmacology

Centre: Clinical Pharmacology

Telephone: +44(0) 20 7882 3403



Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension and translational clinical research.

In 2007, 2009 and 2011 his research has been independently rated amongst the top ten scientific discoveries in his field. In 2009 he won the Lily Prize of the British Pharmacology Society, in 2015 he won the Genome Valley Award at BioAsia and in 2016 the Bjorn Folkow Award of the European Society of Hypertension. Since 2008 he directs the NIHR Biomedical Research Centre at Barts. He was Director of William Harvey Research Institute (2002-2020), elected to the Academy of Medical Sciences in 2008 and was President of the British Hypertension Society (2009-2011).

He is an NHS consultant in the Barts Blood Pressure Clinic within the Barts/William Harvey European Society of Hypertension Centre of Excellence. He raised £25m toward the William Harvey Heart Centre which created a translational clinical research centre and was the academic leader that created the Barts Heart Centre bringing 3 hospitals together in 2015 to create the UK’s largest heart centre (includes UCLH Heart Hospital, the London Chest Hospital and Barts). He served on the 2011 NICE Guideline Group for hypertension and leads the Joint UK Societies’ Working Group and Consensus on Renal Denervation. Since 2014 he has been one of the top 200 most highly cited researchers in the world in genomics according to Thomson Reuters. In 2013 he became an NIHR Senior Investigator.

In 2013 he was appointed Chief Scientist for Genomics England, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection. As chief scientist, Mark leads on all scientific activities for Genomics England. He engages with NHS scientific teams and the general public to promote, explain and enthuse about the 100,000 Genomes Project. He also oversees a coalition of 2500 researchers which comprise the Genomics England Clinical Interpretation Partnership.


Group members

Office of the William Harvey/NIHR Barts Biomedical Research Centre Co-Director’s
Clare Birch (Executive Assistant); Nina Ravic (Education Manager); Gerald McLaren (Institute Manager); Steve Coppen (Deputy Institute Manager); John Whiteley (Chief Operating Officer for the NIHR Barts Biomedical Research Centre).

Cardiovascular Genomics
Dr Helen Warren (Statistical Geneticist); Dr Claudia Cabrera (Bioinformatician); Dr Mike Barnes (Director of Bioinformatics); Dr Bori Mifsud (MRC Career Development Fellow from eMedLab). 

William Harvey Clinical Research Centre
Dr Vivienne Monk (Clinical Research Centre Manager); Dr David Collier (Co-Director); Dr Manish Saxena (Clinical Fellow); Dr Julian Shiel (Clinical Fellow), Anne Zak (Senior Nurse Manager); Marion Benford (Quality Assurance); Mike Taylor (Recruitment); Patrizia Ebano; Jo Hadley; Ania Michalska (Research Sisters).


Cardiovascular Genomics
Since 1996 he has been National Co-ordinator of the MRC British Genetics of Hypertension (BRIGHT) Study on behalf of 5 UK Universities. He led the hypertension study within the Wellcome Trust Case Control Consortium and has since formed and co-leads the Global BP gen consortium and International Consortium for Blood Pressure Genome-wide Studies which combined the talents of 354 scientists from 224 Institutions from 24 Countries. This work has now identified over 212 genes for blood pressure and 5 genes influencing statin response.

Cardiovascular Clinical Trials
He was on the Steering Group of the Anglo-Scandinavian Cardiac Outcome Trial recruiting 1157 hypertensives. This trial has changed international guidance on lipid-lowering and blood pressure treatment. From this Barts and The London now have a major clinical trials programme and a partnership with Quintiles Transnational where we coordinate and enhance clinical research across UCLP Partners Academic Health Sciences Centre.

Key Publications

For a full list of publications click here

* denotes joint last author and # denotes the corresponding author.

  • Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, then 60 co-authors then Colhoun HM, Hitman G, Krauss RM, Wouter Jukema J*, Caulfield MJ*. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014 Oct 28;5:5068. doi: 10.1038/ncomms6068.
  • Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases:
    lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014 May 31;383(9932):1899-911. doi: 10.1016/S0140-6736(14)60685-1.
  • Kottgen A*, then  co-authors then Caulfield M*, Bochud M*, Geiger C*. Multiple Novel Loci Highlighting Metabolic Control of Urate Production and Excretion are Associated with Gout. Nature Genetics 2013. Feb;45(2):145-54. doi: 10.1038/ng.2500. Epub 2012 Dec 23.
  • Georg B. Ehret*, then 346 co-authors then Bruce M. Psaty*, Gonçalo R Abecasis*, Aravinda Chakravarti*, Paul Elliott*, Cornelia M. van Duijn*, Christopher Newton-Cheh*#, Daniel Levy*##, Mark J. Caulfield*##, Toby Johnson*. Genetic variants from novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478 (7367):103-9. Voted top 5 paper in CV research and number 1 in stroke by the American Heart Association.
  • Louise V Wain*, then 248 co-authors- then Mark J Caulfield*, Dabeeru C Rao*, Martin D Tobin*#, Paul Elliott*#, Cornelia M van Duijn*#. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nature Genetics 2011; 43(10):1005-11.
  • Wellcome Trust Case Control Consortium. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls (Caulfield is a co-PI). Nature. 2010; 464 (7289):713-20.
  • Christopher Newton-Cheh*#, then 165 co-authors then Mark Caulfield*#, Patricia B Munroe*#. Eight blood pressure loci identified by genome-wide association study of 34,433 people. Nature Genetics 2009; 41:666-676. Voted American Heart Association Top ten paper in worldwide CV research in 2009
  • Caulfield MJ, et al. (2008) SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008;  5(9): e197.
  • Wellcome Trust Case Control Consortium (Caulfield co-PI). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-678. Voted Best Scientific Research Paper in the World in 2007 (by both Nature and Science).
  • Barter PJ, Caulfield M, etal. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine. 2007 Nov 22;357(21):2109-22.


September 2016 
£6.5m grant to launch new heart disease Biomedical Research Centre
Queen Mary University of London

August 2011
Blood pressure measured at home